New insider activity at United Therapeutics ( (UTHR) ) has taken place on December 23, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Director Louis Sullivan has cashed out a significant portion of his stake in United Therapeutics, selling 5,950 shares of the company’s stock in a transaction valued at $3,047,156. This insider sale highlights a multi-million-dollar move by a member of the company’s board and may draw attention from investors tracking executive and director trading activity at United Therapeutics.
Recent Updates on UTHR stock
In the last 24 hours, United Therapeutics has drawn attention mainly due to a series of upward revisions to analysts’ price targets and the company’s ongoing clinical progress. Multiple firms recently boosted their valuation outlooks following positive developments in the business, particularly the advancement of its xenotransplantation program, highlighted by the first clinical xenotransplantation in the EXPAND study. This milestone appears to have reinforced confidence in the company’s long‑term growth prospects in organ transplantation and pulmonary hypertension therapies, prompting analysts to re-evaluate the potential commercial impact and risk profile of its pipeline. Additionally, investor focus is being maintained through upcoming investor events, such as an Oppenheimer-hosted meeting in New York on December 9, which is expected to provide further updates on strategy and clinical programs. These factors together underpin the recent reassessment of the stock’s future earnings potential and risk-adjusted outlook, which in turn explains the series of upward price target adjustments mentioned across several firms, although exact changes and recommendations were not specified here. Recent price action over the last day is being driven more by these evolving expectations and sentiment around the company’s innovation trajectory than by any single macro event.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics’ strong financial performance and positive earnings call are the most significant factors contributing to the score. The company’s robust revenue growth, profitability, and strategic initiatives provide a solid foundation for future growth. Technical analysis supports a bullish trend, although valuation metrics suggest the stock is fairly valued. The absence of a dividend yield indicates a focus on reinvestment for growth. Potential risks include market competition and regulatory uncertainties.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: 42.63%
Average Trading Volume: 589,456
Technical Sentiment Signal: Buy
Current Market Cap: $22.27B